

NF2 Clinical Pipeline: Active Interventional Drug Therapies

The data provided in this section is for information only and does not constitute medical advice, nor does it constitute an endorsement of any of the clinical activities listed. This information should not be used as basis for you to make any medical decision. Please confer with a physician or medical professional to discuss any of the information listed. Updated: December 12, 2017. For the most current info visit the NF Registry (nfregistry.org) where you can find a list of NF relevant trials that is updated weekly.

NF2	Trial ID	TARGET	Agent	Phase 0	Phase 1	Phase 1/2	Phase 2	Phase 3
Meningioma	NCT02831257	mTOR	AZD-2014					
Meningioma	NCT02523014	FAK and SMO	GSK2256098 and Vismodegib					
Other	2011-001789-16	Multi Kinase Inhibitor	Sorafenib					
Other	2010-023508-28	Tyr-Kinase (BCR-Abl)	Nilotinib					
VS	NCT01767792	VEGF	Bevacizumab (Avastin)					
VS	NCT01125046	VEGF	Bevacizumab (Avastin)					
VS	NCT02129647	Multi kinase (VEGFR)	Axitinib					
VS	NCT01345136	mTOR	Everolimus (RAD001)					
VS	NCT02379754	HSP70	Gentamycin					
VS	NCT02415257	HSP70	Gentamycin					
VS	NCT03079999	NSAID agent	Aspirin					
VS (Bejing only)	NCT02934256	EGFR-TKi	Icotinib					
VS and Meningioma	NCT02282917	HDAC	AR-42					
VS and Meningioma	NCT01880749	mTOR	Everolimus (RAD001)					
All NF2 Tumors	NCT03095248	MEK	Selumetinib					